SCHEMBL4250366

SCHEMBL4250366

CCCCCOC(=O)c1cc(=O)c2cc([N+](=O)[O-])ccc2o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.55
MAPT P10636 2/20 0.46
CACNA1F O60840 2/20 0.46
CACNA1D Q01668 2/20 0.46
CACNA1S Q13698 2/20 0.46
CACNA1C Q13936 2/20 0.46
GABRP O00591 2/20 0.44
GABRD O14764 2/20 0.44
GABRA1 P14867 2/20 0.44
GABRB1 P18505 2/20 0.44
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA5 P31644 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA2 P47869 2/20 0.44
GABRB2 P47870 2/20 0.44
GABRA4 P48169 2/20 0.44
GABRE P78334 2/20 0.44
GABRA6 Q16445 2/20 0.44
GABRG1 Q8N1C3 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249323 0.99 MAOB (0.54) MAOBMAPTCACNA1FCACNA1DCACNA1S
SCHEMBL4246525 0.97 MAOB (0.56) MAOBMAPTCACNA1FCACNA1DCACNA1S
SCHEMBL4251638 0.92 MAOB (0.65) MAOBMAPTGABRPGABRDGABRA1
SCHEMBL4249682 0.91 MAOB (0.55) MAOBMAPTCACNA1FCACNA1DCACNA1S
SCHEMBL4246759 0.90 MAOB (0.54) MAOBMAPTCACNA1FCACNA1DCACNA1S
SCHEMBL4250533 0.88 MAOB (0.56) MAOBMAPTCACNA1FCACNA1DCACNA1S
SCHEMBL4253620 0.88 MAOB (0.66) MAOBMAPTGABRPGABRDGABRA1
SCHEMBL4250542 0.83 MAOB (0.51) MAOBGABRPGABRDGABRA1GABRB1
SCHEMBL4253623 0.83 MAOB (0.65) MAOBMAPTAKR1B1ALDH1A1MEN1
SCHEMBL4254462 0.83 MAOB (0.60) MAOBMAPTAKR1B1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101497571-B Process for producing chromone compound SUMITOMO CO LTD 2012-07-04 CN disclosed
EP-2105432-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-2105431-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
CN-101497571-A Process for producing chromone compound SUMITOMO CHEMICAL CO (JP) 2009-08-05 CN disclosed
CN-100509751-C Process for producing benzopyranone compound SUMITOMO CHEMICAL CO (JP) 2009-07-08 CN disclosed
EP-1867626-A2 Process for producing chromone compound Sumitomo Chemical Company, Limited (JP) 2007-12-19 EP disclosed
CN-1911896-A Process for producing chromone compound SUMITOMO CHEMICAL CO (JP) 2007-02-14 CN disclosed
US-20060217565-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-28 US disclosed
US-7094914-B2 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-22 US disclosed
CN-1649824-A Process for producing benzopyranone compound SUMITOMO CHEMICAL CO (JP) 2005-08-03 CN disclosed
US-20050085664-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LMITED (JP) 2005-04-21 US disclosed
EP-1479667-A1 PROCESS FOR PRODUCING CHROMONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085664-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL MAOB 476/4885MAPT 4765/4885CACNA1F 4517/4885
US-20060217565-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL MAOB 476/4885MAPT 4765/4885CACNA1F 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.